EyeYon Medical

Company Overview

Snapshot

Founded in January 2010 by Nahum Ferera, Arie Marcovich, and Ofer Daphna, EyeYon Medical operates with 11–50 employees. The company has raised a total of $36.14M across 4 funding rounds from 12 investors. In December 2025, EyeYon Medical received FDA IDE approval to initiate a US clinical study for EndoArt, its artificial endothelial layer for corneal edema.

Business overview

EyeYon Medical is a startup specializing in medical ophthalmic devices designed to address complications arising from various corneal diseases, including corneal edema. The company's core technology includes EndoArt, a synthetic implant for treating chronic corneal edema by replacing dysfunctional endothelium, and Hyper CL, an FDA-approved therapeutic contact lens for corneal conditions requiring eye drop treatment. EyeYon Medical serves the ophthalmic market, providing solutions for patients, healthcare providers, and hospitals, operating within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In February 2025, EyeYon Medical announced its expansion into China with the establishment of a new subsidiary, Zhuhai EyeYon Medical Technology Co. This strategic move signals the company's commitment to global market penetration and its intent to capitalize on the growing healthcare market in China, potentially accelerating the adoption of its ophthalmic medical devices and broadening its patient reach.

Company Intelligence Q&A

What is EyeYon Medical's flagship product?

EyeYon Medical's flagship product is EndoArt, an artificial endothelial layer designed as a synthetic implant to treat chronic corneal edema secondary to endothelial dysfunction.

When did EyeYon Medical receive FDA IDE approval for its EndoArt product?

In December 2025, EyeYon Medical received FDA IDE approval to initiate a US clinical study for EndoArt, its artificial endothelial layer for corneal edema.

Which investors participated in EyeYon Medical's March 2021 funding round?

In March 2021, EyeYon Medical received funding from investors including.

What is the purpose of the Hyper CL product?

The Hyper CL is an FDA-approved therapeutic contact lens developed by EyeYon Medical for various corneal conditions that require eye drop treatment.

When did EyeYon Medical expand into China?

In February 2025, EyeYon Medical announced its expansion into China with the establishment of a new subsidiary, Zhuhai EyeYon Medical Technology Co.